Abstract PD-1 blockade therapy has revolutionized cancer treatments. However, a substantial population of patients is unresponsive. To rescue unresponsive patients, the mechanism of unresponsiveness to PD-1 blockade therapy must be elucidated. Using a 'bilateral tumor model' where responsive and unresponsive tumors were inoculated into different sides of the mouse belly, we demonstrated that unresponsive tumors can be categorized into two groups: with and without systemic immunosuppressive property (SIP). The SIP-positive tumors released uncharacterized, nonproteinaceous small molecules that inhibited mitochondrial activation and T cell proliferation. By contrast, the SIP-negative B16 tumor escaped from immunity by losing MHC class I expression. Unresponsiveness of SIP-positive tumors was partially overcome by improving the mitochondrial function with a mitochondrial activator; this was not successful for B16, which employs immune ignorance. These results demonstrated that the 'bilateral tumor model' was useful for stratifying tumors to investigate the mechanism of unresponsiveness and develop a strategy for proper combination therapy.
Introduction
Cancer immunotherapy using immune checkpoint blockade, particularly antibodies against programmed cell death receptor 1 (PD-1) or its ligand (PD-L1), has made a revolution in cancer treatments as this treatment has durable response even to terminal stage cancers and lesser side-effects compared to the conventional cancer treatments (Brahmer et al., 2010; Couzin-Frankel, 2013; Hodi et al., 2010; Mahoney et al., 2015; Topalian et al., 2015) . The success of clinical trials for the PD-1/PD-L1 axis blockade led the FDA to approve antibodies for PD-1 (e.g. nivolumab, pembrolizumab) or PD-L1 (e.g. Atezolizumab, Avelumab, Durvalumab) for different types of human cancers including metastatic non-small cell lung carcinoma (NSCLC), squamous cell lung cancer, renal cell carcinoma, hodgkin's lymphoma, head and neck squamous cell carcinoma, and recently, for microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) cancers that include many latestage cancers (Chowdhury et al., 2018a) .
Despite the impressive success rate of PD-1 blockade therapy, a significant fraction of patients is unresponsive. To further improve its efficacy, we must (i) identify biomarker(s) that predict the responsiveness/unresponsiveness and (ii) develop improved strategy including the combination therapy. For these improvements, we need to understand the mechanism of unresponsiveness to PD-1 blockade therapy. Most studies on biomarkers and resistance mechanisms have focused only on the tumor's intrinsic properties (Cristescu et al., 2018; Ribas, 2015; Rieth and Subramanian, 2018; Wellenstein and de Visser, 2018; Zou et al., 2016) . We need to elucidate the mechanism for unresponsiveness related to immune effector T cells to understand the complicated interaction between cancer and immunity. Several studies have worked on the unresponsive mechanism from the immunity side in different models. In one such model, the 'Cold and Hot tumor hypothesis', tumors can be roughly classified as 'immunologically hot (inflamed)' with an abundance of tumor-infiltrating lymphocytes (TILs) and 'immunologically cold (noninflamed)' with an absence of a sufficient population of pre-existing immune cells (Bonaventura et al., 2019; van der Woude et al., 2017) . In addition, some groups claim that clinical failures in many patients could be due to an imbalance between T-cell reinvigoration and tumor burden (Borcoman et al., 2018; Huang et al., 2017) . CD8 + T cells, the major immune effector cells for attacking tumors, are subject to negative regulation by multiple mechanisms in tumor-bearing hosts. Some of the well-known negative regulatory cells and soluble factors include myeloid-derived suppressor cells (MDSC), innate lymphoid cells (ILC), tumor-associated macrophages (TAM), regulatory CD4 + T cells (Tregs), regulatory B cells (Bregs), transforming growth factor b (TGF-b), interleukin-10 (IL-10), adenosine, granulocyte-macrophage colony-stimulating factor (GM-CSF), prostaglandin E2 (PGE2), and L-Kynurenine (Artis and Spits, 2015; DeNardo and Ruffell, 2019; Facciabene et al., 2012; Sarvaria et al., 2017; Tauriello et al., 2018) . Lack of MHC class I and neo-antigen on tumor cells also cause unresponsiveness because T cells cannot recognize the tumor (Garrido et al., 2016; McGranahan et al., 2017; Rodríguez, 2017) . The tumor microenvironment, influenced by the above mechanisms, allows tumor cells to escape from immune attack (DeNardo and Ruffell, 2019; Russo and Protti, 2017) . Due to this complexity of tumor and immunity interactions, it is difficult to determine which tumor employs which immune escape mechanism.
eLife digest Immunotherapy is a fast-emerging treatment area that turns the body's own immune system against cancer. One powerful group of treatments are the PD-1 blockers. PD-1 is an inducible protein that is sometimes found on healthy immune cells called T cells and normally acts to stop T cells mistakenly attacking healthy cells. However, it can also prevent T cells attacking cancer. This happens when cancer cells make a protein called PD-1 ligand, which interacts with PD-1 to switch off nearby T cells. Antibodies that block PD-1 or PD-1 ligand can reactivate T cells, allowing them to destroy the cancer, but this PD-1 blocking therapy currently works in less than half of all patients who receive the treatment.
To mount a successful defense against cancer, a T cell needs to be able to perform two key tasks: recognize cancer cells and prepare to attack. T cells are alerted to the presence of the disease by MHC class I proteins on the surface of cancer cells holding up small fragments of molecules that are tell-tale sign that the cell is cancerous. To prepare to attack, a T cell depends on its mitochondriathe powerhouses of the cell -to send a cascade of signals inside the T cell that help it to activate and multiply. It is possible that cancer cells escape PD-1 blocking treatments by interfering with either one of these two tasks. They may either hide their MHC class I proteins to become invisible to passing T cells -a phenomenon known as "local immune ignorance"; or they may release longrange molecules to stop T cells preparing to attack -"systemic immune suppression".
To explore these options further, Kumar, Chamoto et al. developed a new tumor model in mice. Each mouse had two tumors, one that responded to PD-1 blocking treatment and one that did not. The idea was that, if the unresponsive tumor was simply hiding from passing T cells, its presence should not affect the other tumor. But, if it was releasing molecules to block T-cell activation, the other tumor could become unresponsive to PD-1 blocking treatment too.
Kumar, Chamoto et al. examined different types of unresponsive tumor in this model system and found that they fell into two groups. The first group simply hid themselves from nearby T cells, while the second group released molecules to dampen all T cells. The identity of these molecules is unknown, but further experiments suggested that they likely work by blocking the mitochondria in T cells. In mice with these tumors, drugs that boosted mitochondria activity made anti-PD-1 treatment more effective.
If the findings in this mouse model parallel those in humans, it could open a new research area for immunotherapy. The next step is for researchers need to identify the molecule responsible for systemic immune suppression. This could help to make PD-1 blocking treatments more effective in people who do not currently respond.
Energy metabolism mediated by mitochondrial activity regulates the fate of T cells. It has been reported that mitochondria play an important role in antigen-specific T cell activation through signaling of mitochondrial-derived reactive oxygen species (ROS) (Mallilankaraman, 2018; Murphy and Siegel, 2013; Sena et al., 2013) . We recently reported that mitochondria are activated in tumorreactive CTLs during PD-1 blockade therapy in MC38 tumor-bearing hosts (Chamoto et al., 2017) . Boosting fatty acid oxidation with a metabolic modulator enhanced the PD-1 blockade effect (Chowdhury et al., 2018b) . Therefore, attenuation of the mitochondrial activity of T cells by tumormediated factors could be an immune escape mechanism.
In this study, we developed a novel approach using a 'bilateral tumor model' and studied the immunosuppressive nature of unresponsive tumors to PD-1 blockade therapy. This model allowed us to categorize unresponsive tumors into two: those which have immune ignorance properties at tumor local sites and the others which have systemic immunosuppressive properties (SIP). SIP is mediated by small molecules to downregulate mitochondrial function directly and to inhibit T cell proliferation. Boosting the mitochondrial activity by the addition of bezafibrate, a pan-PPAR agonist, partially improved the efficacy of the PD-1 blockade against unresponsive tumors with SIP but not for tumors with immune ignorance at the local site.
Results

Different immune responses between hosts with responsive and unresponsive tumors
We first determined which tumor was responsive and unresponsive using an anti-PD-L1 monoclonal antibody (mAb) to block PD-1 signal (PD-1 blockade) or the Pdcd1 -/-mouse model ( Figure 1 -figure supplement 1). As summarized in ' Table 1 ', GL261, MC38, and MethA were characterized as responsive tumors while LLC, B16, Pan02, and CT26 were characterized as unresponsive tumors. Since CD8 + cytotoxic T lymphocytes (CTLs) are the main effector cells during PD-1 blockade therapy, we examined the difference in the host's immune responses to a responsive tumor and an unresponsive tumor according to the schedule shown in Figure 1A . We found both the total lymphocytes and the effector memory CD8 + T cells (defined as CD62L low CD44 high , P3) in draining lymph nodes (DLNs) significantly increased in the group of responsive tumors, but did not change in unresponsive tumor-bearing hosts after PD-1 blockade ( Figure 1B The frequency of CD8 + tumor-infiltrating lymphocytes (TILs) also increased after PD-1 blockade in the group of responsive tumor-bearing hosts, but not in unresponsive tumor-bearing hosts ( Figure 1D ). The expression of T-bet and IFN-g, which reflect the activity of Th1-type cytotoxic activity, increased after PD-1 blockade treatment in the group bearing responsive tumors, but did not in the unresponsive tumor-bearing group (Figure 1E and F; Sullivan et al., 2003) . Similar results were obtained in mice on another genetic background (BALB/c) ( Higher mitochondrial activity of effector CD8 + T cells from mice with responsive tumors after PD-1 blockade
We and others have previously reported that mitochondrial activation in CD8 + T cells is a marker of CTLs activation (Buck et al., 2016; Chamoto et al., 2017) . Thus, to determine whether there was an association between the responsiveness to PD-1 blockade therapy and mitochondrial activation in T cells, we measured several markers of mitochondrial activation using the Seahorse Analyzer (Figure 2-figure supplement 1A) . We found that DLN CD8 + T cells from responsive (MC38 and GL261) tumor-bearing hosts had significantly higher basal respiration, maximal respiration, spare respiratory capacity (SRC), and ATP turnover by PD-1 blockade, which was not observed in unresponsive (B16 and LLC) tumor-bearing hosts ( Classification of unresponsive tumors by the presence or absence of systemic immunosuppressive property (SIP)
To investigate the mechanism of the systemic immune suppression of unresponsive tumors, we next employed a 'bilateral tumor inoculation model' where unresponsive and responsive tumors were inoculated on different sides of the host ( Figure 3A ). This model facilitates disclosing how much humoral factors derived from unresponsive tumors would contribute to the growth of responsive tumors in the other side. As shown in Figure 3B , we found that when unresponsive tumors (LLC or Pan02) were present on the left side, the growth inhibition of the responsive MC38 on the right by the PD-1 blockade therapy was inefficient. However, when the unresponsive B16 was on the left, the responsive MC38 or GL261 were rejected by PD-1 blockade as efficiently as the case in which no tumor was on the left side ( Figure 3B and Following the same experimental design, we performed the bilateral tumor experiment in mice on another background (BALB/c) and identified that CT26 is an unresponsive tumor with SIP ( Figure 3C and Figure 3 -figure supplement 1C). Taken together, we classified unresponsive tumors into two groups: those with or without SIP ( Table 2) .
Tumor-derived suppressive soluble factor(s) systemically inhibits mitochondrial activity of CTLs in vivo
Since we observed mitochondrial activation in CD8 + T cells as a parameter of responsiveness (Fig- ure 2), we used the bilateral tumor model to investigate how immunosuppressive factors released from unresponsive tumors (on the left side) inhibited the immune response against responsive tumors (on the right side) from the aspect of mitochondrial activation ( Figure 4A ). As shown in Figure 4B , the absolute number of lymphocytes in the DLN on the side with MC38 was increased by PD-1 blockade in mice with the SIP-negative B16 on the other side, but not when the SIP-positive LLC was on the other side. Accordingly, mitochondrial ROS production, mass, OCR and ATP turnover in DLN CD8 + T cells were also enhanced by PD-1 blockade on the MC38 side in the presence of B16 on the other side, but not the case when SIP-positive LLC was inoculated on the other side ( Figure 4C and D). In contrast, the PD-1 blockade treatment did not change the mitochondrial activation status in the unresponsive tumor sides (B16 and LLC) ( Figure 4E and F). In summary, while both LLC and B16 were unresponsive, only the LLC systemically inhibited the mitochondrial activation of CTLs during the PD-1 blockade therapy.
The immunotherapy-resistant B16 tumor employs local immunological ignorance
We suspected that unresponsive tumors without SIP may not be recognized by the acquired immunity. We compared tumor growth between wild type and immune-compromised mice (Rag2 -/-). As shown in Figure 5A , the growth of responsive tumors (MC38, GL261, and MethA) was significantly restricted in wild type compared with Rag2 -/-mice. In contrast, unresponsive tumors were more or less insensitive to acquired immunity ( Figure 5B ). Note that some unresponsive tumors with SIP (LLC and CT26) were sensed to a small extent by acquired immunity while unresponsive tumors without SIP (B16) were completely ignored ( Table 2) . This complete ignorance could be attributed to deficiencies in the 'T cell -tumor cell interaction' probably due to less neoantigen and/or lack of MHC class I expression. Indeed, we found that B16 does not express MHC class I even after stimulation with IFN-g, but others do ( Figure 5C and D) . In other words, B16 acquired unresponsiveness by employing local immunological ignorance instead of SIP. These data indicate that one of the mechanisms of unresponsiveness in tumors without SIP is lack of MHC class I expression, and suggest that elimination of the suppressive factor would facilitate the enhancement of PD-1 blockade therapeutic efficacy only in unresponsive tumors with SIP.
Secretion of immune inhibitory small molecules from SIP-positive tumors
To examine whether immune suppressive factors are released from unresponsive tumors, naïve CD8 + T cells were stimulated with anti-(CD3+CD28) mAb-coated beads in the presence of Figure 6A ). Proliferation assays (thymidine incorporation and Ki67 detection assays) demonstrated that T cell proliferation was significantly inhibited in the presence of supernatants from LLC or CT26, but not in the presence of supernatants from B16, GL261 or MethA ( Figure 6B and Figure 6 -figure supplement 1A and B). The suppressive effects of soluble factors from the LLC supernatant was further evidenced by the restoration of T cell proliferation when the supernatant was diluted (Figure 6-figure  supplement 1C ). It is of note that the SIP factor production is not only specific to mouse cell lines, but also to human cell lines ( Figure 6-figure supplement 2) . In addition, different parameters of mitochondrial activation such as cellular ROS and mitochondrial potential were significantly inhibited by the LLC supernatant compared with the B16 and GL261 supernatants ( Figure 6C ). The OCR and the extracellular acidification rate (ECAR), a parameter for glycolytic function, were severely reduced in CD8 + T cells cultured for 48 hrs in the presence of LLC supernatants compared with those from B16 and GL261 ( Figure 6D and E). Similar suppressive activities were observed by supernatants from BALB/c background tumor CT26 ( Figure 6-figure supplement 1D ). To clarify whether this mitochondrial suppression is direct or bystander, we examined mitochondrial activation parameters within 2 hrs of coculture with the supernatant. As shown in Figure 6F , mitochondrial activation parameters were inhibited in the presence of LLC supernatants immediately, indicating that SIP factors highly likely inhibit mitochondrial activity directly, but not cellular transcriptional activity. Indeed, the transcriptional levels of PGC-1a/b, a master regulator of mitochondrial activation, did not change within 2 hrs ( Figure 6 -figure supplement 3A). The SIP factor inhibited B cell mitochondria as well within 2 hrs, showing this suppressive effect is more general (Figure 6-figure supplement 3B ). These results indicate that the immunosuppressive factors released from SIP-positive tumors directly and generally inhibit the mitochondrial function. Further, to understand the molecular properties of suppressive factors, we performed heat-inactivation to denature protein components and used a dextran-coated charcoal (DCC) treatment to adsorb small molecules in the culture supernatants. As shown in Figure 6G and Figure 6 -figure supplement 1E, heat-inactivation of LLC and CT26 culture supernatants did not abolish their suppressive activity, whereas removing low molecular weight compounds using the DCC treatment eliminated their suppressive activity, suggesting that the suppressive factor(s) may be comprised of nonproteinaceous small molecules. We further fractionated the supernatant into 'Fraction A (<3 KDa)' and 'Fraction B (3~50 KDa)' and found that 'Fraction A' had almost the same inhibition potential as the total culture supernatants ( Figure 6H and Figure 6-figure supplement 1F) . Again, removing small molecules from 'Fraction A' using the DCC treatment restored the proliferation of CD8 + T cells. We further tested whether previously reported small molecules could be candidates of the SIP factor such as adenosine, Prostaglandin E2 (PGE 2 ) and kynurenine, the transcriptional levels of key enzymes to produce them were examined. However, there was no relationship between the Table 2 . Mechanistic classification of unresponsive tumors.
Background Name of tumor Releasing suppressive factor (related to Figure 3 ) Activation of acquired immunity (related to Figure 5 suppressive property and the expression levels of enzymes including CD39, CD73, COX-2, mPGES1 and IDO1 ( Figure 6-figure supplement 4) , suggesting the low possibility of known factors.
Combination of bezafibrate with PD-1 blockade improves survival of mice bearing SIP-positive tumors
Since SIP reduced the mitochondrial activity, we examined whether mitochondria activation drug combination can reverse the immune suppression by SIP-positive tumors. As bezafibrate activates mitochondria and synergizes with PD-1 blockade therapy, we first tested whether bezafibrate can reverse the suppression of mitochondrial function and proliferation caused by suppressive factors from the LLC culture supernatants in vitro (Chowdhury et al., 2018b) . Mitochondrial function of naïve CD8 + T cells was regained significantly when bezafibrate was used along with culture supernatant in vitro ( Figure 7A ). Encouraged with these in vitro results, we performed PD-1 blockade combinatorial therapy with bezafibrate for LLC tumor-bearing hosts ( Figure 7B ). We found that the tumor-killing effect by the PD-1 blockade was enhanced and mouse survival was increased in the 
Discussion
One of the biggest issues in PD-1 blockade cancer immunotherapy is how to reduce the rate of unresponsiveness. Although there are many unresponsive mechanisms, cancers employ at least two strategies to escape from the immune attack: local or systemic immune suppression. Some reports have suggested 'hot tumors' and 'cold tumors' to distinguish responsive and unresponsive tumors based on the level of immune cell infiltration in the tumor mass (van der Woude et al., 2017) . However, it is difficult to explain the molecular mechanisms of unresponsiveness by this definition because it explains the results of immune responses in local tumor areas, but not the induction phase of immune escape. In this paper, we employed the bilateral tumor inoculation model, which can distinguish local immune ignorance from systemic immune suppression, and categorized unresponsive tumors into two groups, with or without SIP. Small molecule(s) with less than 3 kDa size which is released from SIP-positive tumors appear to attenuate mitochondria-mediated energy metabolism in T cells. We rule out the known factors such as suppressive cytokines, adenosine, Prostaglandin E2 (PGE 2 ) and kynurenine. Tumor cells show dysregulated cellular metabolism and the metabolic products often induce immune suppression (DeBerardinis, 2008; Munn and Mellor, 2013; Vazquez et al., 2016) . Although it has been reported that methyl-nicotinamide (MNA), which is converted by nicotinamide N-methyl-transferase (NNMT), acts as an immune suppressive factor (Gebicki et al., 2003) , this compound showed no suppression at physiological levels (data not shown). Other metabolites could be candidates, which are derived from the tumor's metabolic activity.
For successful PD-1 blockade therapy, the 'tumor-immunity cycle' needs to operate smoothly (Chen and Mellman, 2013; Pio et al., 2019) . Hindrance in the pathway at any step of antigen recognition, activation, recruitment and killing at the tumor site, DLN or bloodstream would lead to the unresponsive state (Mushtaq et al., 2018) . DLN is generally considered as a place where naïve T cells are primed to effector T cells. Our bilateral tumor model analysis suggests that LLC systemically inhibits T cell priming at DLN of responsive tumor sides via suppressive factors, but B16 does not. However, it seems to contradict that T cells in DLN on the side of B16 were not activated in spite of the deficiency of SIP. This observation suggests that tumor recognition by the local tumor area is critical to trigger T cell priming in DLN and to establish a successful tumor-immunity cycle. Therefore, tumors lacking MHC take advantage of the ignorance or escape mechanism not only in the local tumor area but also in DLN. Given that LLC expresses MHC and is sensitive to the acquired immunity to some extent, it is reasonable that LLC but not B16 is susceptible to the combination therapy. Mitochondrial activation is essential for the full activation of T cells. In our in vitro assay system for mitochondrial activities, we stimulated naïve CD8 + T cells by anti-(CD3+CD28) mAb beads because CD28 in addition to CD3 signal is necessary for robust mitochondrial activation during the proliferation (Klein Geltink et al., 2017) . Although our OCR data suggest that the suppressive factors downregulate the mitochondrial activity, ECAR also severely inhibited. Therefore, the suppressive factors may inhibit glycolysis, resulting in the attenuation of subsequent OXPHOS reactions. This hypothesis agrees with the fact that T cells rely on glycolysis more than OXPHOS when they differentiate from naïve to effector T cells (Menk et al., 2018) . Another possible mechanism for suppression of mitochondrial function by the suppressive factors is inhibition of the downstream signals of CD3 and/or CD28 because these two signals are necessary for the upregulation of glycolysis and OXPHOS in T cells.
In this work, we applied bezafibrate to unresponsive LLC or CT26 tumors. We found this combination therapy partially restored the PD-1 blockade effect per the in vitro assays where bezafibrate partially removed the mitochondrial inhibition by the suppressive factors in the supernatant. This partial effect suggests that under the situation of 'brake' induced by the suppressive factors, the 'acceleration' by PGC-1a/PPAR activation would not fully work. To obtain the maximum benefit, we need to define the suppressive factors and remove the 'brake'. Our data suggest the possibility of unknown small molecules for suppressive factors. The purification of this small molecule by bioassays will enable us to identify its structure by mass spectrometry. Once we know such a compound, we may be able to find the enzymes responsible for the synthesis of this product and target them for combinatorial treatment.
Materials and methods
Animals
C57BL/6N and BALB/c inbred mice were purchased from 'The Charles River Laboratories, Japan (Kanagawa, Japan)'. Pdcd1 -/-and Rag2 -/-inbred mice lines were maintained under specific pathogen-free conditions at the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University. Female, 6-8 weeks-old mice were used in all the experiments.
Cell culture
Cell lines were cultured in RPMI or DMEM medium (Gibco, Grand Island, NY, USA; catalog #11875-093 and 11995-065 respectively) with 10% (v/v) heat-inactivated fetal bovine serum and 1% (v/v) penicillin-streptomycin mixed solution (Nacalai Tesque, Kyoto, Japan, 26253-84) as per the instructions recommended by the ATCC. Cell lines were free of mycoplasma contamination. Cell cultures were maintained at 37˚C with 5% CO 2 in a humidified incubator. Details of different murine cell lines used in the experiment e.g. source of cell lines, background, and origin of cancer, etc. are mentioned in Table 1 . The tumor cell lines MethA and GL261 were passaged in vivo once before use in experiments.
Monotherapy model using anti-PD-L1 antibody were intraperitoneally (i.p.) injected with 80 mg of anti-PD-L1 mAb (clone 1-111A.4); mAb injection was repeated every fifth day. For untreated mice, an isotype control for the anti-PD-L1 mAb (Rat IgG2a, k) was injected. Tumor sizes were measured every alternate day using a digimatic caliper (Mitutoyo Europe GmbH, Germany) and tumor volume was calculated using the formula for a typical ellipsoid [p Â (length Âbreadth Â height)/6]. anti-PD-L1 antibody was injected following a monotherapy treatment model (for the dose of antibody and interval between two injections). Tumor sizes of responsive and unresponsive tumors were measured every alternate day and tumor volume was calculated according to the formula mentioned earlier.
Bilateral tumor model
Chemical reagents
Bezafibrate (Santa Cruz Biotechnology, Dallas, TX, USA) was used at the dose of 5 mg/kg for in vivo combination therapy. Bezafibrate was freshly prepared, immediately before use, in DMSO. Dissolved bezafibrate was diluted in PBS and 200 mL was i.p.-injected per mouse. Bezafibrate was added at the concentration of 5 mM for in vitro assays throughout this work wherever it is used unless specified.
Combination therapy model
For combination therapy experiments, the therapy started when the tumor size was 60-70 mm 3 .
Mice were i.p.-injected with 40 mg of anti-PD-L1 mAb (clone 1-111A.4); the mAb injection was repeated every sixth day. Mice were i.p.-injected with bezafibrate at 5 mg/kg dose every third day. For control groups, an isotype control for the anti-PD-L1 mAb (Rat IgG2a, k) and DMSO vehicle for bezafibrate were injected. All groups were subjected to the same dose of DMSO. Tumor measurement was performed as stated above.
Naïve CD8 + T cell isolation
To isolate naïve CD8 + T cells from C57BL/6N inbred wild-type mice, the spleen and three LNs (axillary, brachial, and inguinal LNs) from both the right and left sides were harvested. The spleen was minced, treated with ACK lysis buffer (0.15 M NH 4 Cl + 1.0 mM KHCO 3 + 0.1 mM Na 2 -EDTA) for 2 min to lyse the erythrocytes, and mixed with pooled and minced LN cells. Naïve (CD62L high CD44 low ) CD8 + T cells were then purified from total pooled lymphocytes according to the manufacturer's instructions (Miltenyi Biotec, . For in vitro analysis, naïve CD8 + T cells were stimulated with anti-CD3 and CD28 mAb-coated dynabeads (Thermo Fisher Scientific, Gibco, Catalog# 11452D).
Collection of culture supernatants from different cell lines
We seeded 0.5 million cells/well in 6-well plates in 4 mL total volume of respective media as recommended by the ATCC. After 48 hrs of incubation, we harvested the culture supernatant, centrifuged at 10,000 x g for 15 min at 22˚C, collected the supernatant, and kept it at À80˚C for storage. We added culture supernatant one-fourth of the total volume in the well (96-well round-bottom plate) throughout the in vitro assays with naïve CD8 + T cells in this work, unless specified.
Thymidine incorporation assay
Thymidine solution diluted in spleen RPMI (Basal RPMI media with 10% FCS, 1% Penicillin-Streptomycin, 50 mM 2-Mercapto ethanol, L-Glutamine, Na-pyruvate, NEAA) was added to cells and incubated for 4 hrs at 37˚C in a humidified incubator with 5% CO 2 . After incubation, cells were transferred to a 96-well filter plate followed by the addition of scintillation buffer. Thymidine uptake was measured on a Microbeta 2 microplate counter (PerkinElmer, # 2450-0120) machine.
Heat-inactivation treatment of supernatant
To inactivate the protein component, culture supernatant was boiled for 10 min at 95˚C followed by centrifugation at 10,000 x g for 30 min. The supernatant was collected and stored at À80˚C for storage.
Dextran-coated charcoal (DCC) treatment of supernatant
To remove small molecules, the supernatant was treated with DCC, which removes small molecules (e.g. nucleotides, vitamins, lipids) from the sample by adsorbing them on the surface. To remove small molecules, 12 mg DCC (for 500 mL supernatant) was added and incubated for 20 min at 25˚C, followed by centrifugation at 10,000 x g for 30 min. After centrifugation, the supernatant that was free from small molecules was collected.
Fractionation of culture supernatant
Cultures supernatants were fractionated into different fractions using amicon ultra-centrifugal filters (Merck Millipore Ltd., Ireland) with cut-off sizes of 3 KDa and 50 KDa. Supernatants were added to 3 KDa filter and centrifuged at 12,000 x g for 30 min at 4˚C. The filtered supernatant was collected and further fractionated using a higher cut-off filter (50 KDa) in a similar way.
Cell preparation for analysis
For draining lymph node (DLN) analysis, axillary, brachial, and inguinal LNs (one of each) were harvested from the tumor-bearing side (left or right flank) of mice. All LNs were minced and pooled. Average LN cell numbers (total pooled LN cells/3) were used as absolute cell numbers. For tumorinfiltrating lymphocyte (TIL) analysis, tumor tissue was harvested and cut into 1-2 mm pieces with scissors followed by digestion with collagenase type IV (Worthington Biochemical Corporation, Lakewood, NJ, Catalog # LS004188) using a gentle MACS Dissociator (Miltenyi Biotec). The numbers of TILs per mg of tumor tissue were used as the absolute numbers.
Flow cytometry analysis
The following monoclonal antibodies (mAbs) were used to detect the respective antigens during FACS staining: CD8 (53-6.7), CD62L (MEL-14), CD44 (IM7), CD45.2 (104), T-bet (4B10), IFN-g (XMG-1.2) from BioLegend (San Diego, CA, USA); and Ki67 (SolA15) from eBioscience (San Diego, CA, USA). All flow cytometry experiments were performed on a FACS Canto II (BD Biosciences, Franklin Lakes, NJ, USA), and analyzed using the FlowJo software (FLOWJO, LLC, Ashland, OR, USA). Mitochondrial mass, membrane potential, mitochondrial superoxide, and cellular ROS were determined by MitoTracker Green, MitoTracker Deep Red, MitoSOX Red, and CellROX Green reagents, respectively (all from Life Technologies, Carlsbad, CA, USA). The cells were washed twice with D-PBS buffer followed by the addition of dye solution with final concentrations of 0.125, 0.125, 5.0, and 0.625 mM, respectively, in RPMI media and incubated at 37˚C in a 5% CO 2 humidified incubator for 30 min. After incubation, cells were washed twice with D-PBS buffer followed by surface staining.
Intranuclear staining
For intranuclear staining, cells were fixed and permeabilized using the Foxp3 staining kit (Thermo Fisher Scientific, Catalog # 00-5523-00) following the manufacturer's instructions. After fixation and permeabilization, cells were incubated with the respective antibody for 15 min at 4˚C in the dark, followed by washing with FACS buffer (PBS, 0.5-1% BSA or 5-10% FBS, 0.1% NaN3 sodium azide).
Intracellular cytokine staining for IFN-g
Homogenized tumor mass cells from in vivo treated experimental mice were incubated for 4 hrs at 37˚C in a 5% CO 2 humidified incubator. After incubation, Brefeldin A and Monensin (eBioscience, Invitrogen, Carlsbad, CA, USA; catalog # 4506-51 and 4505-51 respectively) were added at the concentration of 5 mg/mL and 2 mM as per the manufacturer's instructions and incubated for further 2 hrs. Following a total of six hours of incubation, cells were washed once with D-PBS and further stained for surface proteins, if any. Cells were then fixed with 1.5% paraformaldehyde solution (incubated for 15 min at 4˚C) and washed twice with FACS buffer. Cells were then treated with 0.5% Triton-X-100 in PBS and incubated for 15 min at 4˚C to permeabilize the cells. Monoclonal antibodies to IFN-g were added (the concentration was pre-optimized) and incubated for 15 min at 4˚C followed by washing with FACS buffer.
qRT-PCR
We isolated RNA from the experimental groups with the RNeasy mini kit (QIAGEN, Hilden, Germany) and synthesized cDNA by reverse transcription (Invitrogen). The primers used to perform quantitative reverse transcription PCR (qRT-PCR) are listed here. The primers pairs used were FP: TACCACCCCATCTGGTCATT, RP: GGACGTTTTGTTTGGTTGGT for CD39; FP: CAAATCCCACA-CAACCACTG, RP: TGCTCACTTGGTCACAGGAC for CD73; FP: CAAGGGAGTCTGGAACATTG, RP: ACCCAGGTCCTCGCTTATGA for COX2; FP: ATGAGTACACGAAGCCGAGG, RP: CCAGTA TTACAGGAGTGACCCAG for mPGES1; FP: CACTGAGCACGGACGGACTGAGA, RP: TCCAATGC TTTCAGGTCTTGACGC for IDO1; FP: CGGAAATCATATCCAACCAG, RP: TGAGGACCGC TAGCAAGTTTG for PGC-1a; FP: GGTGTTCGGTGAGATTGTAGAG, RP: GTGATAAAACCGTGCTTC TGG for PGC-1b; and FP: TATTGGCAACGAGCGGTTCC, RP: GGCATAGAGGTCTTTACGGATGT for b-actin. b-actin was used as loading control.
Measurement of oxygen consumption rates and extracellular acidification rate
The oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) of treated cells were measured using an XF e 96 Extracellular Flux analyzer (Seahorse Biosciences, North Billerica, MA, USA). One day before the experiment, first the XF e 96 plate was coated with CellTak solution as per the manufacturer's recommendation. On the day of the experiment, all chemicals (e.g. Oligomycin, FCCP, and Rotenone/Antimycin A) were prepared in OCR media as per the manufacturer's recommendation and the machine was calibrated using the calibrant buffer in the calibrant plate prior to the experiment. 400 thousand cells per well were seeded in the precoated XF e 96 plate and the OCR/ECAR was measured. Different parameters from the OCR graph were calculated. ATP turnover was defined as follows: (last rate measurement before oligomycin) -(minimum rate measurement after oligomycin injection). Maximal respiration was defined as follows: (maximum rate measurement after FCCP) -(non-mitochondrial respiration). Spare respiratory capacity (SRC) was calculated by subtracting basal respiration from maximal respiration. We measured the ECAR value in the same well, which contained an optimal glucose level so the basal ECAR (or glycolysis) value is the reading we obtained immediately before oligomycin injection. We prepared the assay medium as described in the XF cell Mito Stress Test Kit (Kit 103015-100). The glucose concentration in this medium is 10 mM. In the classical glycolytic assay procedure (glucose-free media) the final concentration of glucose added to the port was 10 mM while measuring flux. The basal ECAR value in this classical method is calculated by subtracting the last rate measurement before the glucose injection from the maximum rate measurement before the oligomycin injection, which gives essentially the same value if calculated by our method. Glycolytic capacity was defined as the rate measured after the oligomycin injection. The glycolytic reserve was defined as follows: (glycolytic capacity) -(basal ECAR value).
Statistics
Statistical analysis was performed using Prism 6 (GraphPad Software, La Jolla, CA, USA). One-way ANOVA analysis followed by Sidak's multiple comparison test was utilized to analyze three or more variables. To compare two groups, student's t-test was used. All statistical tests were two-sided assuming parametric data, and a p-value of <0.05 was considered significant. The variations of data were evaluated as the means ± standard error of the mean (SEM). Five or more samples were thought to be appropriate for the sample size estimate in this study. Samples and animals were randomly chosen from the pool and treated. No blinding test was used for the treatment of samples and animals.
Study approval
Mice were maintained under specific pathogen-free conditions at the Institute of Laboratory Animals, Graduate School of Medicine, Kyoto University under the direction of the Institutional Review Board.
